Refine Search
Article Categories
Strategy Tags
- Direct lending (5)
- Distressed (1)
- Emerging markets (1)
- High yield bonds (13)
- Investment grade credit (4)
- Structured credit (4)
- CLO (15)
- Distressed debt (3)
- Leveraged loans (remove)
- Synthetic/SRT (5)
- High Yield/Unrated (1)
- ABL Financing (1)
Geography Tags
-
Euro loan trading: CLOs hang up on top speed-dial contact
5 years ago
Telco Altice, the most prevalent holding for European CLOs, became the most sold issuer of the month, but ION Corporates was the most popular -
Schroders integrates ESG into corporate revolving credit facility
5 years ago
The firm is the first asset manager to convert its corporate revolving credit facility into an ESG-linked facility, it claims, and will link pricing to three ESG-related key performance indicators -
Purdue Pharma bankruptcy highlights value of ESG analysis
5 years ago
Purdue Pharma's bankruptcy this week, and the sector wide concern over the US opioid epidemic, has highlighted the utility of environmental, social and governance (ESG) standards in credit analyses -
Euro loan trading: Areas caters to CLOs while managers cast away Nets
5 years ago
Global travel catering services Areas flew off the shelf after it allocated its €1.05 billion term loan B, with 50 CLO managers buying the loan -
Prepayments pose reinvestment dilemma for CLO managers
5 years ago
CLO managers globally could be left sitting on piles of cash amid an uptick in loan prepayments. Standard & Poor’s reported that institutional US loan prepayments had hit $26 billion in July, and more recently some widely-held CLO names are set to return principal to lenders, with financial data provider Refinitiv US Holdings and Italian telecom operator Wind Tre taking this route. -
Aircraft lessors: gathering clouds lead to talk of turbulence
6 years ago
Aircraft leasing companies have been cruising over the past two years as passenger numbers grew, but rising interest rates and trade tariff concerns are making some bondholders nervous -
Drug makers: desperately seeking pain relief
7 years ago
With Teva’s profitable Copaxone being undermined by cheaper alternatives, the company is in need of a pick-me-up. By Euan Hagger -
Payday: Investors go for broke on regulatory bet
7 years ago
New regulations could seriously hamper US payday lenders – but bond holders are betting the rules won’t be enacted -
Alcentra continues hot fundraising streak with new global credit offering
7 years ago
BNY Mellon subsidiary Alcentra has attracted $140 million for a corporate credit fund
Want all the latest news, comment, analysis and data?
